Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SkyePharma Solaraze

Executive Summary

Diclofenac gel, 3%, approved for actinic keratoses Oct. 16. The company is in discussions with a potential North American marketing partner. The gel should be applied to lesion areas twice daily; the recommended duration of therapy is from 60 to 90 days. The NDA (21-005) was filed Oct. 22, 1998
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS036795

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel